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production of sleep abnormalities and expression of positive and 
negative symptoms. These data indicate the need for systematic 
trials of cholinergic and anticholinergic agents in the treatment of 
positive and negative symptoms of schizophrenia, respectively. 
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Although poor response to neuroleptics has traditionally been 
considered a characteristic feature of negative schizophrenic 
symptoms, several recent studies have documented significant im- 
provement in negative symptoms in schizophrenic patients treated 
with neuroleptics. The question of whether neuroleptic-induced im- 
provement in negative symptoms is linked to concomitant im- 
provement in positive symptoms or occurs independently of such 
improvement is unresolved; it is also unclear if this profile is simi- 
lar during treatment with clozapine and typical neuroleptics. To 
address these issues, we studied 120 RDC/DSM-III-R schizo- 
phrenic inpatients at drug-free baseline and after 3-4 weeks of 
treatment with clinically-determined doses of typical neuroleptics. 
We also studied 40 RDUDSM-III-R schizophrenic patients before 
a trial of clozapine and after 4-6 weeks of initiating clozapine 
treatment. Positive and negative symptoms were assessed by the 
BPRS “THOT” factor and the SANS sum of global scores, re- 
spectively. During treatment with typical neuroleptics, there was 
significant improvement in both positive symptoms (15.6k2.9 to 
10.2k3.2) and negative symptoms (12.5k4.2 to 8.6k3.4); the 
change in positive symptoms was highly correlated to the change 
in negative symptoms (~0.60; p<O.OOl). During treatment with 
clozapine, both positive symptoms (from 16.of 3.6 to 12.4f3.5) 
and negative symptoms (from 13.8f4.5 to 10.5f4.1) improved 
significantly; change in positive symptoms was again significantly 
correlated to change in negative symptoms (1=0.63; p<O.Ol). Al- 
though there are sample differences between the two groups mak- 
ing comparisons difficult, these data indicate that negative 
symptoms improve along with positive symptoms in the course 
of initial neuroleptic treatment, both with typical neuroleptics and 
clozapine. Clozapine’s apparent greater efficacy on negative 
symptoms may bc related to its greater efficacy on positive symp- 
toms (in otherwise treatment-refractory patients) and its lower pro- 
pensity to cause EPS. 
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In a previous study, we found a low concentration of plasma 
interleukin (IL)-la in neuroleptic-free patients with schizophrenia. 
In view of the considerable overlap in the cellular sources and 
biological activity of IL-l, IL-6 and tumor necrosis factor (TNF), 
it was thought necessary to examine all three of the relevant 
cytokines in schizophrenic patients. This study denonstrated that 
the concentration of plasma IL-6 was significantly higher in the 
patients taking neuroleptic drugs (5.95k1.20 pmol/L, n=32) than 
in those not taking neuroleptic drugs(4.8lU.13 pmol/L, n=13, 
p<O.Ol), but was not significantly higher than in normal control 
subjects (5.04+1.78 pmol/L, n=9, p>O.O5). Kruskal-Wallis analy- 
sis of’ variance revealed a significant difference in the concen- 
tration of plasma IL-6 among the patients taking neuroleptic drugs, 
those not taking neurolpetic drugs and normal control subjects 
(H=7.1, df=2, p<O.O5). The increased plasma IL-6 was not 
related to the clinical state of the patients taking neuroleptic drugs. 
No significant differences of plasma IL-ID and TNF-a were found 
between the three groups. These results suggest that neuroleptic 
treatment may increase only IL-6 production, and that the low 
concentration of plasma IL-a found in our previous study may 
be peculiar to schizophrenia. 
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We recently reported on a review of the medical records of the 
first 37 patients to begin clozapine treatment at a state hospital 
in Oregon. Records were reviewed for the six months before 
clozapine treatment and six months after. Patients had a long his- 
tory of schizophrenia and had responded poorly to antipsychotic 
medication. Clozapine treatment was generally well tolerated, al- 
though the rate of seizures (8%) was slightly higher than expected. 
Psychotic symptoms decreased as measured by the Brief Psychi- 
atric Rating Scale, as did symptoms of tardive dyskinesia, as 
measured by the Abnormal Involuntary Movement Scale. Thirty- 
four patients remained hospitalized after six months of treatment. 
However, indicators of social function (hospital privilege level, 
community passes, violent episodes, and episodes of seclusion and 
restraint) all showed that patients improved markedly after receiv- 
ing clozapine. We will present data extending this analysis to in- 
clude a six month follow-up of 100 patients, with 68 of the 
patients followed for eighteen months. 
